Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell ...(led to the identification of small molec...),Health

Date:5/18/2009

led to the identification of small molecules and biologics that can direct stem cell proliferation and function. Fate Therapeutics is developing these small molecule and biologic SCMs to modulate the activity of adult stem cells to stimulate healing or block cancer growth.

"Fate's distinct and unique approach of using small molecules and biologics in stem cell medicine provides a well-defined regulatory path and allows the Company to move quickly into clinical programs to ultimately meet the needs of patients," said Dr. Multani. "This role represents to me one of the most exciting in the industry as we are applying the power of small molecule and biologic drug development, where we can use clearly defined safety and efficacy endpoints, to the revolutionary field of stem cell biology in order to develop new medicines for diseases and conditions that currently have limited to no treatment options."

Prior to joining Fate Therapeutics, Dr. Multani was Vice President of Translational Medicine at Kalypsys, Inc. since 2007, where he advanced the development of multiple compounds in the therapeutic areas of pain and inflammation and metabolic diseases. From 2005 to 2007 as Senior Vice President of Clinical Development and then Chief Medical Officer at Kanisa Pharmaceuticals, Dr. Multani led the clinical development of zosuquidar as well as a companion diagnostic in acute myeloid leukemia. From 2004 to 2005 as Vice President of Clinical Development at Salmedix, he led three clinical development programs in hematologic malignancies and solid tumors. From 1999 to 2004 advancing from Associate Director of Oncology and Hematology to Senior Director of Medical Research at Biogen-Idec, Dr. Multani led or provided strategic direction for multiple drug development programs in Phase 1 to Phase 4 clinical trials, including Zevalin(R) and Rituxan(R).

Before his career in industry, Dr. Multani held academic and clinical positi
'/>"/>

SOURCE Fate Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
2. Nile Therapeutics Reports 2009 First Quarter Financial Results
3. Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
4. Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
5. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
6. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
7. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $20 Million of Common Stock and Warrants
9. Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
10. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
11. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA